Slide 1: Arctic Bioscience H1 2026 Financial Results
Arctic Bioscience Presentation of financial results; First half year 2026 August 27th 2026 Christer L. Valderhaug (CEO) Runhild Gammelsæter (Medical Director) Jone R. Slinning (CFO)
Slide 2: Disclaimer
Disclaimer Matters discussed in this correct, and their methodology ascertain from the information Presentation may constitute or may be forward-looking and published by that third party, no include forward-looking speculative. facts have been omitted that statements. Forward-looking would render th
Slide 3: Developing and commercializing pharmaceutical and nutraceutical products
Developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds, utilizing proprietary technology and methodology
Slide 4: Agenda
Agenda Intro and H1-2026 operational highlights Operational review Nutra Operational review Pharma H1-2026 consolidated Group financial review Business outlook Q&A
Slide 5: Intro and H1-2026 operational highlights
Intro and H1-2026 operational highlights 5
Slide 6: H1-2026 highlights
H1-2026 highlights HRO350 inflammation data sharpen the path forward Phase III design, EMA scientific advice and partnership discussions are the next steps Systemic inflammation data Nutra revenue +35.2% US market +87% published in the peer-reviewed NOK 23.3m in H1 2026 versus NOK 17.2m in NOK 9.7m
Slide 7: Operational review Nutra
Operational review Nutra 7
Slide 8: B2C: product differentiation drives growth
B2C: product differentiation drives growth PRODUCT PROPERTIES COMMERCIAL STATUS 3:1 DHA : EPA Stable Norway sales both online and offline The B2C portfolio drive commercial growth in new ROMEGA® is a premium phospholipid-DHA markets both in Europe as well as the APAC region, omega-3 supplement in ad
Slide 9: B2B: pipeline and recurring customers support growth
B2B: pipeline and recurring customers support growth CURRENT STATUS Demand & customers Robust order pipeline and recurring revenue from long-standing customer relationships support the 2026 outlook The American market had a very positive development in the first half year, with a revenue of NOK 9.7
Slide 10: China: strong partnership and a clear H2 growth signal
China: strong partnership and a clear H2 growth signal CURRENT STATUS PRODUCT PLATFORM Strategic partner The partnership with Kotler / Tromso Nutrition Technology remains strong Market presence A ROMEGA® concept store has been established in Hainan’s free-trade zone Demand signal Purchase orders ind
Slide 11: Operational review Pharma
Operational review Pharma 11
Slide 12: Pharmaceutical pipeline: Outlook
Pharmaceutical pipeline: Outlook ABS302 HRO350 ABS403 Brain development in Mild to moderate Psoriasis Glaucoma extremely premature infants Next steps Next steps Next steps • Partner search (funding phase 3) • Produce material and conduct • Dialogue on a larger follow up study on • Publish results/ar
Slide 13: Psoriasis: An immune-mediated inflammatory disease of the skin
Psoriasis: An immune-mediated inflammatory disease of the skin Inflammation described by Aulus Cornelius Celsus (25 BC – 50 AD) by the four cardinal signs: • Redness, swelling, heat and pain Psoriasis described by Hippocrates (460-377 BC): • Psora (itch) and lopoi (scaling) Picture: Psoriasis_nummal
Slide 14: Consistent reduction in systemic inflammation in two clinical trials
Consistent reduction in systemic inflammation in two clinical trials Two clinical trials in patients with mild-to-moderate psoriasis HeROPA study Haukeland study (52-week placebo control, N=521) (26-week placebo control, N=60) * * * SII25: ≥25% SII reduction; SII40: ≥40% SII reduction Baseline After
Slide 15: Resolve - not block - inflammation: a therapeutic frontier
Resolve - not block - inflammation: a therapeutic frontier Herring roe PLs promote SPM biosynthesis in macrophages and a keratinocyte/fibroblast coculture as a model of psoriasis Specialized pro-resolving mediators (SPMs) is a superfamily of lipid mediators that actively resolve inflammation • Most
Slide 16: Immunomodulatory effects on cytokine pathways
Immunomodulatory effects on cytokine pathways Herring roe oil exerts immunomodulatory effects on the IL-17/23 signalling axis in immune and skin cells as models for psoriasis Aim: whether signalling pathways in skin and immune cells relevant to the pathophysiology of psoriasis are affected by herrin
Slide 17: Preclinical and clinical data as part of potential future medical approval
Preclinical and clinical data as part of potential future medical approval Cellular data aligning with clinical results • Marketing Authorisation for a medicine is given based on pre-clinical data and safety and efficacy from several clinical trials (phase 3) • HRO350 has completed phase 2b and furt
Slide 18: Next steps HRO350 psoriasis: Phase 3 design with experts
Next steps HRO350 psoriasis: Phase 3 design with experts • External experts will assist with phase 3 protocol design • CRO and potential partners to contribute to final protocol Key elements to integrate based on learnings from phase 2b • Choice of primary endpoint • Take SII baseline into account
Slide 19: Extremely premature infants (ABS302)
Extremely premature infants (ABS302) • Smerud Medical Research International • Setting up consortium with partners and advisors for pre-clinical studies (efficacy and toxicology) • Considering public grants with European consortium Next steps • Produce material and conduct preclinical studies • Seek
Slide 20: H1-2026 consolidated group financial review
H1-2026 consolidated group financial review 20
Slide 21: Key financial figures
Key financial figures SALES REVENUES GROSS MARGIN AVAILABLE LIQUIDITY 23,3 33,4% 5,5 22,6 5,2 29,8% 17,2 22,3% 1,2 H1-2025 H2-2025 H1-2026 H1-2025 H2-2025 H1-2026 30.06.2025 31.12.2025 30.06.2026
Slide 22: Income statement
TNOK H1-2026 H1-2025 Income statement Total revenue 25 038 18 696 Significant sales revenue growth Sales rev enue 23 300 17 230 • Growth in sales revenue of 35,2 % compared to H1-2025 Other income 1 738 1 466 • Strong order intake end of 2025 has materialized in first half of Cost of goods sold 16 3
Slide 23: Breakdown of Nutra revenue
Breakdown of Nutra revenue REVENUE BY BUSINESS LINE REVENUE BY REGION 25 000 25 000 16 % 20 000 20 000 15 000 15 000 22 % 42 % 90 % 10 000 10 000 30 % 86 % 28 % 29 % 5 000 5 000 14 % 10 % 20 % 13 % - - H1-2025 H1-2026 H1-2025 H1-2026 B2C B2B Norway Europe Americas APAC
Slide 24: Cash flow development
Cash flow development TNOK H1-2026 H1-2025 Profit/loss before tax -18 017 -18 945 Profit/loss from sale of tangible assets 0 -5 Ordinary depreciation 2 228 2 573 Change in inv entory -5 859 -3 577 Available liquidity end of period of NOK 1,2 million Change in accounts receiv able -811 4 048 Change i
Slide 25: Financial position
TNOK 30.06.2026 31.12.2025 ASSETS Non-current assets: Financial position I ntangible assets 212 523 212 529 Property, plant and equipment 21 877 22 813 Total non-current assets 234 400 235 342 Current assets: I nv entories 35 482 29 623 Accounts receiv able 11 016 10 206 Other current assets 7 478 8
Slide 26: Business outlook
Business outlook 26
Slide 27: Growth outlook is positive — execution and funding remain important
Growth outlook is positive — execution and funding remain important 01 COMMERCIAL SCALE 02 SUPPLY POSITION 03 PHARMA & CAPITAL GROW DIFFERENTIATE DE-RISK Robust order pipeline and Strategic positioning and product Additional HeROPA publications recurring customers support differentiation are becomin
Slide 28: Arctic Bioscience
ARCTIC Bioscience
Slide 29: Contact
Contact CEO - Christer L. Valderhaug: christer@arctic-bioscience.com CFO - Jone R. Slinning jone@arctic-bioscience.com Medical Director - Runhild Gammelsæter: runhild@arctic-bioscience.com Subscribe to news www.arctic-bioscience.com/investors/home